Linkify statement about lower efficacy of Novavax in South Africa

The basic data were already there from the press release, but add the study paper courtesy de-facto
ljl-covid · Mar 4, 2021 · bdd9cc9 · bdd9cc9
1 parent f9727a8
commit bdd9cc9
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -340,7 +340,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose](https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), as announced by Gamaleya in a press release, where it was also specified that no significant adverse reactions have occurred; the international price for this vaccine was stated as being below $10
 * [The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials](https://sputnikvaccine.com/newsroom/pressreleases/the-sputnik-v-vaccine-s-efficacy-is-confirmed-at-91-4-based-on-data-analysis-of-the-final-control-po/) as announced in a subsequent Gamaleya press release, where it is stated that "the research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals" and that "the Gamaleya Center will create a report that will be used to submit for accelerated registration of the Sputnik V vaccine in various countries"
 * [Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly](https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00) in a press release where they disclose that while the vaccine produces an immune response similar to COVID-19 patients when administered to people between 18 and 49 years, the response in older adult is insufficient
-* [Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3), as announced in a press release by the company about their NVX-CoV2373 protein-based vaccine, based on a trial that included 27% over the age of 65, and on an interim analysis after 62 cases developed, of which 56 were in the placebo group; at the same time, in the South Africa Phase 2b clinical trial, 60% efficacy was attained, possibly due to 90% prevalence of the South African escape variant, which the company says has initiated development of boosters for
+* [Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3), as announced in a press release by the company about their NVX-CoV2373 protein-based vaccine, based on a trial that included 27% over the age of 65, and on an interim analysis after 62 cases developed, of which 56 were in the placebo group; at the same time, [Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant] in South Africa was 60% (among HIV-negative individuals), likely due to 90% prevalence of the South African escape variant, which the company says has initiated development of boosters for
 * [Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial](https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial), with an overall efficacy of 66% using a single-shot scheme, although the efficacy was 72% in the US and 57% in South Africa, possibly owing to the variant there (95% of cases), and 85% effectiveness in preventing severe disease, and the vaccine was well tolerated
 * [Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext) presents the first phase 3 results for the Sputnik V vaccine, with an estimated efficacy of 91.6%, and no serious adverse effects associated with vaccination
 * [GSK and CureVac to develop next generation mRNA COVID-19 vaccines](https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/) and [CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants](https://www.curevac.com/en/2021/02/05/curevac-and-uk-government-to-collaborate-on-development-of-vaccines-against-sars-cov-2-variants/) open the road to multi-variant mRNA vaccines by these companies